Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Nicholas Bowler"'
Autor:
Adam C. Schneider, Thenappan Chandrasekar, Nicholas Bowler, Ryan Fogg, Joon Yau Leong, Andrew Gusev, Linda H. Rodgers, Shelley R. McCormick, Douglas M. Dahl, Jason A. Efstathiou, Michael L. Blute, Anthony L. Zietman, Chin-Lee Wu, Matthew R. Smith, Eliezer M. Van Allen, Adam S. Feldman, Keyan Salari
Publikováno v:
Journal of Urology. 209:1112-1119
Autor:
Edouard J. Trabulsi, James Ryan Mark, Costas D. Lallas, Nicholas Bowler, Thenappan Chandrasekar, Adam Schneider, Hanan Goldberg, Leonard G. Gomella
Publikováno v:
Urology. 155:101-109
Objective To assesses if active surveillance (AS) is an appropriate treatment modality for patients with intermediate risk (IR) prostate cancer (PCa) utilizing population-level data to compare the survival outcomes of men with low risk (LR) and IR PC
Autor:
Israa Salem, Nicholas Bowler, Lucia R. Languino, Fabio Quaglia, Amrita Singh, Rachel M. DeRita, Alexander Duffy, Luca S Sirman, Shiv Ram Krishn, Aejaz Sayeed, Nicole M Naranjo
Publikováno v:
Cancer drug resistance (Alhambra, Calif.)
Cells are known to release different types of vesicles such as small extracellular vesicles (sEVs) and large extracellular vesicles (LEVs). sEVs and LEVs play important roles in intercellular communication, pre-metastatic niche formation, and disease
Autor:
Thenappan Chandrasekar, Nicholas Bowler, Adam Schneider, Hanan Goldberg, James R. Mark, Edouard J. Trabulsi, Costas D. Lallas, Leonard G. Gomella
Publikováno v:
Urology. 155
Autor:
Mark Mann, Leonard G. Gomella, William Kevin Kelly, Nicholas Bowler, Joseph K Izes, Thenappan Chandrasekar, Perry R. Weiner, Ayako Shimada, Veda N. Giri, Edouard J. Trabulsi, Anne Calvaresi, Patrick Mille, Miranda Tsang, James Ryan Mark, Jessica Russo, Donald Preate, Costas D. Lallas, Nathan Handley, Carey McDougall, Laura Gross, Colette Hyatt, Irvin H. Hirsch
Publikováno v:
JCO Precis Oncol
JCO precision oncology, vol 5, iss 5
JCO precision oncology, vol 5, iss 5
PURPOSE Germline testing (GT) for prostate cancer (PCA) is now central to treatment and hereditary cancer assessment. With rising demand for and shortage of genetic counseling (GC), tools to deliver pretest informed consent across practice settings a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29377e1dafb4a3762bfa25cb309061d8
https://europepmc.org/articles/PMC8462590/
https://europepmc.org/articles/PMC8462590/
Autor:
Adam S. Feldman, Joon Yau Leong, Nicholas Bowler, Thenappan Chandrasekar, Ryan N. Fogg, Adam Schneider, Michael L. Blute, Anthony L. Zietman, Douglas M. Dahl, Keyan Salari, Jason Efsathiou, Andrew Gusev
Publikováno v:
Journal of Urology. 206
Autor:
Lucia R. Languino, Shiv Ram Krishn, Andrea Friedman, Stephen C. Peiper, Carmine Fedele, Senem Kurtoglu, Aejaz Sayeed, Alexander Duffy, Adam Hawkins, Madhukar L. Thakur, Amrita Singh, Chirayu P. Goswami, William Kevin Kelly, Renato V. Iozzo, Sushil K. Tripathi, Kerith Wang, Nicholas Bowler
Publikováno v:
Matrix Biology. 77:41-57
The αvβ3 integrin has been shown to promote aggressive phenotypes in many types of cancers, including prostate cancer. We show that GFP-labeled αvβ3 derived from cancer cells circulates in the blood and is detected in distant lesions in NOD scid
Autor:
Costas D. Lallas, Thenappan Chandrasekar, Adam Schneider, Hanan Goldberg, Edouard J. Trabulsi, James Ryan Mark, Nicholas Bowler, Leonard G. Gomella
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:While active surveillance (AS) is an established standard of care for low-risk (LR) prostate cancer (PCa), its utility for favorable intermediate risk (fIR) PCa is less e...
Publikováno v:
International Journal of Law and Psychiatry. 57:61-66
In the United Kingdom (UK) the prison population has increased by around one third since the turn of the millennium amid growing concern over the correctional mission of prisons, the number of prisoners exhibiting mental health difficulties and high
Autor:
Jason A. Efstathiou, Michael L. Blute, Anthony L. Zietman, Nicholas Bowler, Thenappan Chandrasekar, Adam Schneider, Ryan Fogg, Joon Yau Leong, Keyan Salari, Douglas M. Dahl, Andrew Gusev, Adam S. Feldman
Publikováno v:
Journal of Clinical Oncology. 39:225-225
225 Background: Active surveillance (AS) is the preferred management strategy for men with low-risk prostate cancer. However, approximately one in three men on AS experience progression of disease leading to treatment within 5 years, highlighting an